Vertex Pharmaceuticals reported positive Phase 2b data for its kidney disease drug, inaxaplin, showing significant proteinuria reductions in two patient cohorts. This data reinforces the drug's potential and supports its ongoing Phase 2/3 study, with an analyst reiterating an Outperform rating due to its underappreciated value.
Vertex Pharmaceuticals announced encouraging Phase 2b results for inaxaplin, a drug targeting APOL1-mediated kidney disease (AMKD). The data showed significant reductions in proteinuria in patients with modest proteinuria and those with type 2 diabetes, aligning with previous Phase 2a findings. This positive clinical update de-risks the drug's development pathway and provides a strong foundation for the ongoing Phase 2/3 AMPLITUDE study, which could lead to accelerated approval. For traders, this is a positive catalyst for VRTX, reinforcing its long-term growth potential in the biotech space, as highlighted by William Blair's 'underappreciated' view and Outperform rating. The next key milestone is the interim analysis of the AMPLITUDE study in early 2027.